Latest News

Tiziana Life Sciences Hosting Key Opinion Leader Virtual Event to Discuss the Intranasal Delivery of Foralumab in Multiple Sclerosis

11 March 2022

Monday, March 14th @ 11 am ET, registration details below

NEW YORK, March 11, 2022 – Tiziana Life Sciences Ltd (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, announced today that...

Read more

Tiziana Announces Positive Clinical Data from A Secondary Progressive Multiple Sclerosis Patient Treated for Six Months with Intranasally Administered Foralumab, A Fully Human Anti-CD3 Monoclonal Antibody

10 March 2022

  • Intranasal foralumab was well-tolerated with no adverse reactions or laboratory abnormalities after 6 months of therapy and the patient chose to remain on therapy
  • Data show sustained inhibition of microglial activation as assessed by Positron Emission Tomography (PET) along with downregulation...

Read more

KOL Event - 14 March 2022 at 11am ET

04 March 2022

Read more

StemPrintER Demonstrates Prognostic Utility in TransATAC Cohort

01 March 2022

New York, March 1, 2022 - Tiziana Life Sciences Ltd.’s (Nasdaq: TLSA) former subsidiary, AccuStem Sciences, Inc. (OTC PINK: ACMSY) (formerly AccuStem Sciences Ltd.), today announced publication of new data in the European Journal of Cancer. Results demonstrate that StemPrintER...

Read more

Tiziana Life Science's Presentation at the Bio CEO & Investor Conference 2022

11 February 2022

Read more

Tiziana Life Sciences CEO to Present at Annual BIO CEO & Investor Conference

10 February 2022

February 10, 2022, New York, NY – Tiziana Life Sciences Ltd (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, announced today that Dr Kunwar Shailubhai, Chief Executive Officer and Chief...

Read more

Page 3 of 35 Previous Next